Dementia Drugs Market Size - Global Industry, Share, Analysis, Trends and Forecast 2022 - 2030
CHAPTER 1. Industry Overview of Dementia Drugs Market
1.1. Definition and Scope
1.1.1. Definition of Dementia Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Dementia Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Dementia Drugs Market By Drug Class
1.2.3. Dementia Drugs Market By Distribution Channel
1.2.4. Dementia Drugs Market By Region
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restraint 1
3.2.2. Restraint 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Dementia Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Dementia Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Regulatory Compliance
3.9. Competitive Landscape, 2021
3.9.1. Player Positioning Analysis
3.9.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Dementia Drugs Market By Drug Class
4.1. Introduction
4.2. Dementia Drugs Revenue By Drug Class
4.2.1. Dementia Drugs Revenue (USD Billion) and Forecast, By Drug Class, 2018-2030
4.2.2. Glutamate Inhibitors
4.2.2.1. Glutamate Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
4.2.3. MAO Inhibitors
4.2.3.1. MAO Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
4.2.4. Cholinesterase Inhibitors
4.2.4.1. Cholinesterase Inhibitors Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 5. Dementia Drugs Market By Distribution Channel
5.1. Introduction
5.2. Dementia Drugs Revenue By Distribution Channel
5.2.1. Dementia Drugs Revenue (USD Billion) and Forecast, By Distribution Channel, 2018-2030
5.2.2. Hospital Pharmacies
5.2.2.1. Hospital Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.3. Retail Pharmacies
5.2.3.1. Retail Pharmacies Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
5.2.4. Others
5.2.4.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2018-2030
CHAPTER 6. North America Dementia Drugs Market By Country
6.1. North America Dementia Drugs Market Overview
6.2. U.S.
6.2.1. U.S. Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
6.2.2. U.S. Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
6.3. Canada
6.3.1. Canada Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
6.3.2. Canada Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
6.4. North America PEST Analysis
CHAPTER 7. Europe Dementia Drugs Market By Country
7.1. Europe Dementia Drugs Market Overview
7.2. U.K.
7.2.1. U.K. Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
7.2.2. U.K. Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
7.3. Germany
7.3.1. Germany Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
7.3.2. Germany Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
7.4. France
7.4.1. France Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
7.4.2. France Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
7.5. Spain
7.5.1. Spain Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
7.5.2. Spain Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
7.6. Rest of Europe
7.6.1. Rest of Europe Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
7.6.2. Rest of Europe Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
7.7. Europe PEST Analysis
CHAPTER 8. Asia Pacific Dementia Drugs Market By Country
8.1. Asia Pacific Dementia Drugs Market Overview
8.2. China
8.2.1. China Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.2.2. China Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.3. Japan
8.3.1. Japan Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.3.2. Japan Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.4. India
8.4.1. India Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.4.2. India Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.5. Australia
8.5.1. Australia Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.5.2. Australia Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.6. South Korea
8.6.1. South Korea Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.6.2. South Korea Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.7. Rest of Asia-Pacific
8.7.1. Rest of Asia-Pacific Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
8.7.2. Rest of Asia-Pacific Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
8.8. Asia Pacific PEST Analysis
CHAPTER 9. Latin America Dementia Drugs Market By Country
9.1. Latin America Dementia Drugs Market Overview
9.2. Brazil
9.2.1. Brazil Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.2.2. Brazil Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.3. Mexico
9.3.1. Mexico Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.3.2. Mexico Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.4. Rest of Latin America
9.4.1. Rest of Latin America Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
9.4.2. Rest of Latin America Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
9.5. Latin America PEST Analysis
CHAPTER 10. Middle East & Africa Dementia Drugs Market By Country
10.1. Middle East & Africa Dementia Drugs Market Overview
10.2. GCC
10.2.1. GCC Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.2.2. GCC Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.3. South Africa
10.3.1. South Africa Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.3.2. South Africa Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.4. Rest of Middle East & Africa
10.4.1. Rest of Middle East & Africa Dementia Drugs Revenue (USD Billion) and Forecast By Drug Class, 2018-2030
10.4.2. Rest of Middle East & Africa Dementia Drugs Revenue (USD Billion) and Forecast By Distribution Channel, 2018-2030
10.5. Middle East & Africa PEST Analysis
CHAPTER 11. Player Analysis Of Dementia Drugs Market
11.1. Dementia Drugs Market Company Share Analysis
11.2. Competition Matrix
11.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
11.2.2. New Product Launches and Product Enhancements
11.2.3. Mergers And Acquisition In Global Dementia Drugs Market
11.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 12. Company Profile
12.1. Janssen Pharmaceuticals, Inc.
12.1.1. Company Snapshot
12.1.2. Business Overview
12.1.3. Financial Overview
12.1.3.1. Revenue (USD Billion), 2021
12.1.3.2. Janssen Pharmaceuticals, Inc. 2021 Dementia Drugs Business Regional Distribution
12.1.4. Product /Service and Specification
12.1.5. Recent Developments & Business Strategy
12.2. Biogen Pharmaceuticals
12.3. Forest Laboratories, Inc.
12.4. Eli Lilly and Company
12.5. Novartis AG
12.6. Sanofi S.A.
12.7. AstraZeneca
12.8. F. Hoffmann-La Roche
12.9. Merck and Co., Inc.
12.10. Valeant Pharmaceutical International
12.11. Eisai, Inc.
12.12. Pfizer Inc.
12.13. Teva Pharmaceuticals Industries Ltd.
Frequently Asked Questions
What is the size of global dementia drugs market in 2021?
The market size of dementia drugs market in 2021 was accounted to be USD 15.5 Billion.
What is the CAGR of global dementia drugs market during forecast period of 2022 to 2030?
The projected CAGR of dementia drugs market during the analysis period of 2022 to 2030 is 8.7%.
Which are the key players operating in the market?
The prominent players of the global dementia drugs market are Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca, F. Hoffmann-La Roche, Merck and Co., Inc., Valeant Pharmaceutical International, Eisai, Inc., Pfizer Inc., and Teva Pharmaceuticals Industries Ltd.
Which region held the dominating position in the global dementia drugs market?
North America held the dominating dementia drugs during the analysis period of 2022 to 2030.
Which region registered the fastest growing CAGR for the forecast period of 2022 to 2030?
Asia-Pacific region exhibited fastest growing CAGR for dementia drugs during the analysis period of 2022 to 2030.
What are the current trends and dynamics in the global dementia drugs market?
Increasing number of dementia cases, rising prevalence of Alzheimer’s in the world, and growth in cases of chronic disorders drives the growth of global dementia drugs market.
Which drug class held the maximum share in 2021?
Based on drug class, MAO inhibitors segment is expected to hold the maximum share dementia drugs market.
Select Licence Type
Connect with our sales team
Why Acumen Research and Consulting
100%
Customer Satisfaction
24x7+
Availability - we are always there when you need us
200+
Fortune 50 Companies trust Acumen Research and Consulting
80%
of our reports are exclusive and first in the industry
100%
more data and analysis
1000+
reports published till date
